[High frequency of dyslipidemia in VIH-infected patients in aa peruvian public hospital]

Area of Science:

• Internal Medicine
• Infectious Diseases
• Cardiology

Background:

• Dyslipidemia is a metabolic disorder characterized by abnormal levels of blood lipids.
• HIV infection and its treatment, particularly highly active antiretroviral therapy (HAART), are associated with an increased risk of cardiovascular disease, including dyslipidemia.
• Understanding the prevalence and risk factors for dyslipidemia in HIV patients is crucial for effective cardiovascular risk management.

Purpose of the Study:

• To determine the frequency and characteristics of dyslipidemia in HIV-infected patients undergoing HAART at a Peruvian public hospital.
• To identify factors associated with dyslipidemia in this patient population.

Main Methods:

• A cross-sectional study was conducted involving 538 HIV patients who had received HAART for at least six months.
• Dyslipidemia was diagnosed based on the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) criteria.
• Statistical analysis, including adjusted odds ratios, was performed to identify associated factors.

Main Results:

• The overall frequency of dyslipidemia was 74.7% among the studied HIV patients.
• HAART regimens containing protease inhibitors (PI) (OR: 1.22) and patient age over 40 years (OR: 1.17) were significantly associated with dyslipidemia.
• These associations remained significant after adjusting for viral load, CD4 lymphocyte count, and gender.

Conclusions:

• Dyslipidemia is highly prevalent in HIV patients on HAART in this Peruvian cohort.
• The use of protease inhibitors (PI) in HAART regimens is a primary risk factor for dyslipidemia.
• Integrated management strategies for dyslipidemia are essential for comprehensive HIV care.